Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January ...

(Reuters) - Gilead Sciences and the U.S. government have settled ... and deliver innovative therapeutics to people with life-threatening diseases." Spokespeople for the U.S. Department of Health ...

Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...

Global leaders must urgently prioritise and work to provide access to new long-acting HIV prevention -- and potentially ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Salesforce, Inc. (CRM), Shell plc ...

Gilead Sciences, US Government Settle Patent Case ... and deliver innovative therapeutics to people with life-threatening diseases." Spokespeople for the U.S. Department of Health and Human ...

(Reuters) - Gilead Sciences and the U.S. government have settled a billion ... and deliver innovative therapeutics to people with life-threatening diseases." Spokespeople for the U.S. Department of ...